Table 1.
Patient characteristics
| Patient characteristics | N [%] | Median [IQR]; survival: Median [CI] |
|---|---|---|
| Number of patients | 85 [100%] | |
| Age (years) | 73.1 [11.4] | |
| Estimated overall survival time (months) | 11.4 [8.0-14.7] | |
| >50% PSA decline from baseline | 39 [46%]; n = 80, follow up not present for 5 patients. | |
| PSMA therapy | ||
| Number of cycles | 3.0 4 | |
| Cumulated activity (GBq) | 19.3 [24.8] | |
| Baseline blood parameters | ||
| Alkaline phosphatase (U/l) | 147.0 [193.0] | |
| Lactate dehydrogenase (U/l) | 316.5 [227.0] | |
| Aspartate aminotransferase (U/l) | 32.5 [24.0] | |
| Alanine transaminase (U/l) | 16.0 [11.0] | |
| Hemoglobin (g/dl) | 10.4 [2.4] | |
| Prostate-specific antigen (ng/ml) | 284.0 [805.0] | |
| Metastases | ||
| Bone | 78 [92%] | |
| Lymph node | 68 [80%] | |
| Liver | 26 [31%] | |
| Lung | 20 [24%] | |
| Brain | 1 [1%] | |
| Previous therapies | ||
| Docetaxel | 68 [80%] | |
| Cabazitaxel | 20 [24%] | |
| Abiraterone | 72 [85%] | |
| Enzalutamide | 72 [85%] | |
Blood parameters were not available for all patients; Abbreviations: Std = standard deviation; CI = confidence interval.